Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Liabilities and Shareholders Equity (2022 - 2026)

Rallybio's Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $62.3 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 8.58% to $62.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $238.9 million, a 29.51% decrease, with the full-year FY2025 number at $62.3 million, down 8.58% from a year prior.
  • Liabilities and Shareholders Equity hit $62.3 million in Q4 2025 for Rallybio, down from $67.7 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for RLYB hit a ceiling of $180.4 million in Q4 2022 and a floor of $51.0 million in Q2 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $101.3 million across 4 years, with a median of $92.4 million in 2024.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 8.58% in 2025, down 44.82% in 2025.
  • Tracing RLYB's Liabilities and Shareholders Equity over 4 years: stood at $180.4 million in 2022, then crashed by 35.92% to $115.6 million in 2023, then tumbled by 41.09% to $68.1 million in 2024, then dropped by 8.58% to $62.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for RLYB at $62.3 million in Q4 2025, $67.7 million in Q3 2025, and $51.0 million in Q2 2025.